ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2025

Abstract Number: 2704

Complete metabolic response on PET/CT in giant-cell arteritis-related large vessel vasculitis : comparison of two strategies using glucocorticoids or glucocorticoids + tocilizumab

Hubert De Boysson1, Anael Dumont2, Thibault Orvain2, Olivier Espitia3, Cloé Comarmond4, Samuel Deshayes5, Laurent Sailler6, Jean-François Alexandra7, Maxime Samson8 and Achille Aouba5, 1Internal Medicine, CHU Caean, Caen, France, 2Caen University Hospital, Caen, Basse-Normandie, France, 3CHU de Nantes, Nantes, France, 4Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U942, Paris, France, 5Caen University Hospital, Caen, France, 6CHU Toulouse, Toulouse, France, 7Internal Medicine, Hôpital Bichat, APHP, Paris, France, 8CHU Dijon Bourgogne, Dijon, France

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2025

Keywords: giant cell arteritis, Imaging, Therapy, complementary

Session Information

Date: Wednesday, October 29, 2025

Title: Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II (2699–2704)

Session Type: Abstract Session

Session Time: 12:45PM-1:00PM

Background/Purpose: Persistent large-vessel vasculitis (LVV) on PET/CT in giant-cell arteritis (GCA) is associated with a higher risk of aortic dilation. Few data are available on complete metabolic response under treatment (i.e., total extinction of vascular uptakes). This study compared the ability of glucocorticoids (GC) alone and GC + tocilizumab (TCZ) to obtain a complete metabolic response on repetitive PET/CT.

Methods: Through the French Large-Vessel Vasculitis Study Group (GEFA), we retrospectively enrolled all GCA patients who satisfied the following criteria: 1) a LVV was evidenced on PET/CT; 2) all patients were treated either with GC alone or GC+TCZ; and 3) at least a second PET/CT was repeated under the same initial treatment. Patients who received another treatment between the two repeated PET/CT were excluded. Patients who showed a total vascular extinction on repeated PET/CT without LVV relapse during follow-up were considered as a success. Patients with still positive PET/CT or with LVV relapse during follow-up were considered as failures.

Results: A total of 167 patients were enrolled, 76 treated with GC alone and 91 treated with GC + TCZ. Their characteristics at baseline are shown and compared in Table 1. LVV was diagnosed on PET/CT at GCA diagnosis in 66% and 71% (p=ns) of patients in the GC and GC+TCZ groups, respectively. A second PET/CT was repeated at 8 [IQR 25-75, 6–11] months in the GC group and 12 [10–20] months in the GC+TCZ group (p< 0.0001). Under GC alone, 41% of PET/CT showed a total extinction of vascular uptakes versus 76% in the TCZ group (p< 0.0001). Figure 1 shows the proportion of negative PET/CT in the two groups according to the time of control. LVV relapse on a third PET/CT was diagnosed in 5% of patients treated with GC alone and 12% of patients treated with GC+TCZ (p=0.17). At last follow-up, more patients treated with GC+TCZ had discontinued GC (79% vs. 61% in patients treated with GC alone, p=0.009).

Conclusion: This study suggests that the combination of GC+TCZ is more efficient than GC alone to obtain a complete metabolic extinction on repeated PET/CT in GCA-related large vessel vasculitis. A further longitudinal study is required to analyze the impact on the risk of aortic dilation.

Supporting image 1Table 1. Comparison of GC alone and GC+TCZ to obtain a PET/CT extinction in GCA-related LVV

Supporting image 2Figure 1. Proportion of negative PET/CT in the two groups according to the time of control.


Disclosures: H. De Boysson: AbbVie/Abbott, 1, 2, Chugai, 2, Fresenius Kabi, 1, 2, Novartis, 2; A. Dumont: None; T. Orvain: None; O. Espitia: Novartis, 2; C. Comarmond: Roche, 5; S. Deshayes: None; L. Sailler: None; J. Alexandra: Chugai France, 2; M. Samson: AbbVie/Abbott, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Chugai, 2, Fresenius Kabi, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2, 5, Vifor Pharma, 2; A. Aouba: None.

To cite this abstract in AMA style:

De Boysson H, Dumont A, Orvain T, Espitia O, Comarmond C, Deshayes S, Sailler L, Alexandra J, Samson M, Aouba A. Complete metabolic response on PET/CT in giant-cell arteritis-related large vessel vasculitis : comparison of two strategies using glucocorticoids or glucocorticoids + tocilizumab [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/complete-metabolic-response-on-pet-ct-in-giant-cell-arteritis-related-large-vessel-vasculitis-comparison-of-two-strategies-using-glucocorticoids-or-glucocorticoids-tocilizumab/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/complete-metabolic-response-on-pet-ct-in-giant-cell-arteritis-related-large-vessel-vasculitis-comparison-of-two-strategies-using-glucocorticoids-or-glucocorticoids-tocilizumab/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology